Loading...

Expanding Radioisotope Production Will Fuel Global Personalized Medicine

Published
10 Feb 25
Updated
19 Sep 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
26.8%
7D
3.9%

Author's Valuation

€22.8528.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 19 Sep 25

Fair value Increased 5.46%

The upward revision in Eckert & Ziegler’s price target reflects modest improvements in both future P/E and net profit margin, resulting in a new consensus fair value of €22.85. What's in the News Confirmed 2025 earnings guidance with expected sales of approximately €320 million and EBIT before special items of about €78 million.

Shared on 04 Sep 25

With no material changes in either the discount rate or future P/E ratio, analysts left Eckert & Ziegler’s fair value estimate effectively unchanged at €21.67. What's in the News Eckert & Ziegler confirmed 2025 guidance, expecting sales of around €320 million and EBIT before special items of around €78 million.

Shared on 01 May 25

Fair value Decreased 66%

Shared on 23 Apr 25

Fair value Decreased 0.24%

AnalystConsensusTarget has increased revenue growth from 7.8% to 9.1% and increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 9.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.80%

Shared on 26 Mar 25

Fair value Increased 0.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Decreased 3.90%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.